Blog
RSS FeedPosted by Michael Wonder on 27 Mar 2023
Finerenone for the treatment of chronic kidney disease in patients with type 2 diabetes
23 March 2023 - NICE has issued evidence-based recommendations on the use of finerenone (Kerendia) for the treatment of adults ...
Posted by Michael Wonder on 25 Mar 2023
NICE recommends life-changing gene therapy for children with ultra rare genetic disorder in final draft guidance
23 March 2023 - The first and currently only gene therapy for children with an ultra-rare genetic disorder has been recommended ...
Posted by Michael Wonder on 22 Mar 2023
Nivolumab in combination with chemotherapy for the neo-adjuvant treatment of patients with resectable non-small-cell lung cancer
22 March 2023 - NICE has published evidence based recommendations on the use of nivolumab (Opdivo) in combination with chemotherapy ...
Posted by Michael Wonder on 08 Mar 2023
NICE recommended weight loss drug to be made available in specialist NHS services
8 March 2023 - Thousands of people will soon be able to be prescribed a drug to help them lose weight ...
Posted by Michael Wonder on 06 Mar 2023
Ozempic-like weight loss drug Wegovy coming to the UK market, and it will cost a fraction of what Americans pay
3 March 2023 - Major drug store chains in the United Kingdom plan to start selling the weight loss drug Wegovy, ...
Posted by Michael Wonder on 03 Mar 2023
ABPI response to Government Statutory Scheme rise
2 March 2023 - The Government has confirmed plans to raise the revenue clawback rate paid by pharmaceutical firms subject ...
Posted by Michael Wonder on 02 Mar 2023
Asfotase alfa for the treatment of certain patients with paediatric-onset hypophosphatasia
1 March 2023 - This evaluation reviews the evidence for asfotase alfa for the treatment of patients with paediatric‑onset hypophosphatasia (HST6), ...
Posted by Michael Wonder on 01 Mar 2023
ABPI sets out new proposals to support the NHS and economic growth
1 March 2023 - The pharmaceutical industry’s offer includes an annual £1 billion boost to the NHS as well as an ...
Posted by Michael Wonder on 01 Mar 2023
Eight digitally enabled therapies to treat depression and anxiety in adults conditionally recommended by NICE
1 March 2023 - Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by ...
Posted by Michael Wonder on 01 Mar 2023
Eptinezumab for the prevention of migraine
1 March 2023 - The recommendation was made after consideration of the evidence submitted by Lundbeck, a review of this submission ...
Posted by Michael Wonder on 28 Feb 2023
Baricitinib for the treatment of patients with severe alopecia areata
28 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Feb 2023
Axicabtagene ciloleucel for the treatment of adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after two or more systemic therapies
28 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access ...
Posted by Michael Wonder on 27 Feb 2023
Doctor with Stage 4 cancer is refused access to lifesaving treatment on the NHS
27 February 2023 - Dr Asha Umrawsingh, 50, was first diagnosed with breast cancer in 2010. ...
Posted by Michael Wonder on 23 Feb 2023
Vir Biotechnology announces positive final draft guidance on sotrovimab from the UK’s NICE
22 February 2023 - Final draft guidance based on cost effectiveness evaluation of sotrovimab. ...
Posted by Michael Wonder on 23 Feb 2023
Daratumumab in combination with lenalidomide and dexamethasone for the first-line treatment of patients with multiple myeloma when stem cell transplantation is unsuitable
22 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...